Fifth Third Wealth Advisors LLC Acquires 1,675 Shares of Kenvue Inc. $KVUE

Fifth Third Wealth Advisors LLC grew its holdings in Kenvue Inc. (NYSE:KVUE) by 3.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,212 shares of the company’s stock after purchasing an additional 1,675 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Kenvue were worth $946,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of KVUE. Pittenger & Anderson Inc. bought a new stake in shares of Kenvue in the first quarter valued at approximately $30,000. Trust Co. of Vermont raised its position in shares of Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after purchasing an additional 1,150 shares during the period. TruNorth Capital Management LLC bought a new stake in shares of Kenvue in the first quarter valued at approximately $36,000. Truvestments Capital LLC bought a new stake in Kenvue during the 1st quarter worth approximately $37,000. Finally, Clal Insurance Enterprises Holdings Ltd lifted its stake in Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after purchasing an additional 1,287 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $16.68 on Friday. The company’s fifty day moving average price is $19.15 and its 200-day moving average price is $21.32. The firm has a market capitalization of $32.00 billion, a price-to-earnings ratio of 22.53, a PEG ratio of 2.39 and a beta of 0.72. Kenvue Inc. has a one year low of $15.47 and a one year high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 annualized dividend and a dividend yield of 5.0%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. Kenvue’s payout ratio is 112.16%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several recent analyst reports. Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a research note on Monday, August 11th. UBS Group lowered their target price on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating on the stock in a research note on Wednesday. Canaccord Genuity Group lowered their target price on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. JPMorgan Chase & Co. lowered their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Royal Bank Of Canada lowered their target price on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating on the stock in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and a consensus price target of $21.18.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.